Company profile for Upstream Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Upstream Bio is a biotech company that strives to reach the source of inflammation and conquer it. The company's lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor which is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases, allowing medical professionals to ease the burden of inflammatory and allergic...
Upstream Bio is a biotech company that strives to reach the source of inflammation and conquer it. The company's lead program is a clinical-stage monoclonal antibody that inhibits the TSLP receptor which is a validated target positioned upstream of multiple signaling cascades that affect a variety of immune cells pivotal to common and rare diseases, allowing medical professionals to ease the burden of inflammatory and allergic diseases with novel therapeutics on patients.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
460 Totten Pond Rd. Suite 420 Waltham, MA 02451
Telephone
Telephone
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Natural Product Expo West

Natural Product Expo West

Not Confirmed

envelop Contact Supplier

Natural Product Expo West

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2026/03/01/3246934/0/en/Upstream-Bio-Presents-Additional-Analyses-from-the-Phase-2-VIBRANT-Trial-of-Verekitug-in-Chronic-Rhinosinusitis-with-Nasal-Polyps-at-2026-AAAAI-Annual-Meeting.html

GLOBENEWSWIRE
01 Mar 2026

https://www.globenewswire.com/news-release/2026/02/26/3245409/0/en/Upstream-Bio-to-Present-Additional-Analyses-from-Phase-2-VIBRANT-Trial-in-Chronic-Rhinosinusitis-with-Nasal-Polyps-in-Late-Breaking-Session-at-AAAAI-Annual-Meeting-2026.html

GLOBENEWSWIRE
26 Feb 2026

https://www.globenewswire.com/news-release/2026/02/25/3244446/0/en/Upstream-Bio-to-Participate-in-Upcoming-March-Investor-Conferences.html

GLOBENEWSWIRE
25 Feb 2026

https://www.fiercebiotech.com/biotech/upstream-posts-tezspire-asthma-efficacy-phase-2-falls-short-best-case-scenario

FIERCE BIOTECH
12 Feb 2026

https://www.globenewswire.com/news-release/2026/02/10/3235860/0/en/Upstream-Bio-to-Host-Webcast-to-Report-Top-Line-Results-from-the-Phase-2-VALIANT-Trial-of-Verekitug-in-Patients-with-Severe-Asthma.html

GLOBENEWSWIRE
10 Feb 2026

https://www.globenewswire.com/news-release/2026/01/05/3212596/0/en/Upstream-Bio-to-Present-at-the-44th-Annual-J-P-Morgan-Healthcare-Conference.html

GLOBENEWSWIRE
05 Jan 2026

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty